AbbVie
Skyrizi Approved for Crohn’s Disease Treatment
AbbVie announced the FDA’s approval of Skyrizi as the first specific interleukin-23 inhibitor for treatment ...
JUNE 24, 2022
FDA Warns of Serious Risks, Including Death, With JAK Inhibitors
The FDA is requiring the addition of warnings about increased risks for cancer, serious cardiovascular events and ...
SEPTEMBER 2, 2021
FDA Approves Adalimumab Biosimilar
The FDA has approved adalimumab-bwwd (Hadlima, Samsung Bioepis Co.), a biosimilar referencing adalimumab (Humira, ...
JULY 31, 2019
FDA Grants Pediatric Indication for Mavyret for HCV
An estimated 23,000 to 46,000 children have HCV infection in the United States.
MAY 6, 2019
FDA Approves Cyltezo, Biosimilar of Humira
Second new adalimumab biosimilar approved for multiple indications.
AUGUST 29, 2017
FDA Approves Mavyret for HCV Genotypes 1-6
Knowing which of the six distinct HCV genotypes there are can help inform treatment. Approximately 75% of Americans ...
AUGUST 8, 2017
